711. Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)

BACKGROUND: Exebacase (CF-301) is a novel, recombinantly-produced, bacteriophage-derived lysin (cell wall hydrolase) which is the first lysin to report Phase 2 (Ph2) results which demonstrated 42.8% higher clinical responder rates with a single dose of exebacase used in addition to standard of care...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Open Forum Infect Dis
Hoofdauteurs: Anastasiou, Diane, Cassino, Cara, Schuch, Raymond
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2019
Onderwerpen:
Abstracts
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811034/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.779
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items